## **Proton therapy**

#### Joris Hartman, MD, PhD Nikhef colloquium, Friday 12 April 2019

### **Personal background**

- Physics 1999 2009
- Medicine 2002 2013
- Master Nikhef 2006 2009
- PhD student @ ANTARES, Nikhef 2009-2010
- PhD student @ UMC Utrecht 2013-2018
  - Feasibility of MRI-guided proton therapy



### **Personal background**

- Physics 1999 2009
- Medicine 2002 2013
- Master Nikhef 2006 2009
- PhD student @ ANTARES, Nikhef 2009-2010
- PhD student @ UMC Utrecht 2013-2018
  - Feasibility of MRI-guided proton therapy



# Currently working on MC validation (physics) and in psychiatry (medicine).



- I. Radiotherapy: a short introduction
- II. Proton therapy: what?
- III. Proton therapy: why?
- IV. Proton therapy: how?
- V. Challenges and developments

### I. Radiotherapy: a short introduction



### What is radiotherapy

"In radiotherapy, ionizing radiation is used to treat cancer"  $^{\dagger}$ 

<sup>†</sup>And some other, benign, conditions

### What is radiotherapy

#### "In radiotherapy, ionizing radiation is used to treat cancer"







<sup>†</sup>And some other, benign, conditions

### What is radiotherapy

#### "In radiotherapy, ionizing radiation is used to treat cancer"



#### 50% of patients treated with radiation therapy

<sup>†</sup>And some other, benign, conditions

Dose  $D = \mathbf{\Phi} \frac{S}{\rho}$ or  $D = 0.1602 \, \mathbf{\Phi} \frac{S}{\rho} \, Gy \, (or \, \frac{J}{kg})$ 

with  $\boldsymbol{\Phi}$  in Gp/cm<sup>2</sup> and S/ $\boldsymbol{\rho}$  in MeV/(g/cm<sup>2</sup>)

Based on tumor type and location



- A. tumor control probability (TCP)
- B. normal tissue complication probability (NTCP)

Based on tumor type and location



#### **Example dose:**

Prostate:	74 Gy (external) up to 200 Gy (internal, <sup>125</sup> I)		
Glioblastoma:	50 Gy		
Melanoma:	30 Gy		
TBI:	12 Gy		
Fatal:	4 Gy (50% of patients)		

#### **Example dose:**

Prostate:	74 Gy (external) up to 200 Gy (internal, <sup>125</sup> I)		
Glioblastoma:	50 Gy		
Melanoma:	30 Gy		
TBI:	12 Gy		
Fatal:	4 Gy (50% of patients)		

#### Limit the toxic effects by **hyperfractionation**

#### **Radiation treatment**

#### **DNA damage**

Linear Energy Transfer (LET) dE/dl in keV/ $\mu$ m

→ Differs per particle type (higher in **heavy charged particles**)

#### **Radiation treatment**

#### **DNA damage**

Linear Energy transfer (LET) dE/dl in keV/um

→ Differs per particle type (higher in **heavy charged particles**)

	Direct damage	VS	Indirect damage
	Direct ionization		Production of free
	of target		radicals
γ/e⁻	~ 1/3		$\sim 2/3$
p <sup>+</sup> /C/	predominant		

### 'Regular' treatment: linac



### 'Regular' treatment: linac





#### **Multileaf collimator**

### 'Regular' treatment: linac



#### 'Regular' treatment: dose distributions







Intensity Modulated Radiotherapy

Zelig Tochner, PTCOG 57

#### 'Regular' treatment: dose distributions



#### Intensity Modulated Radiotherapy

#### improvement

Zelig Tochner, PTCOG 57

#### **Dose Volume Histogram**





#### **Before treatment**

Most used: Computed Tomography (CT)

Better: Magnetic Resonance Imaging (MRI)



#### **Before treatment**

Most used: Computed Tomography (CT) Better: Magnetic Resonance Imaging (MRI)

#### **During treatment**

Planar X-Ray: kilovolt or megavolt Cone-beam CT



#### **Before treatment**

Most used: Computed Tomography (CT) Better: Magnetic Resonance Imaging (MRI)

#### **During treatment**

Planar X-Ray: kilovolt or megavolt Cone-beam CT GTV

CBCT

#### Image guided: MR-Linac

#### Integration of a 1.5T MRI with a linear accelerator









Joris Hartman

Nikhef colloquium, 12-04-2019

### II. Proton therapy: what?









Wilson RR. Radiological use of fast protons. Radiology. 1946 Nov;47(5):487-91.





*"These properties make it possible to irradiate intensely a strictly localized region within the body"* 

Wilson RR. Radiological use of fast protons. Radiology. 1946 Nov;47(5):487-91.





1946: Idea

1954: First treatment

2018: First in NL

*"These properties make it possible to irradiate intensely a strictly localized region within the body"* 

Wilson RR. Radiological use of fast protons. Radiology. 1946 Nov;47(5):487-91.

### **Stopping power**

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

#### **Stopping power**





### **Stopping power**







depth

H. Paganetti "Proton Therapy Physics" Taylor & Francis / CRC Press



Single beam = **pencil beam** 

Clinical energies: 70 – 250 MeV

Energy determines range, can only deliver high dose to small volume

Combination of 100's to 1000's of pencil beams used in a treatment plan



Higher energy (range) Increased range straggling



Higher energy (range) Increased range straggling

#### Range straggling



# For water (in cm): $\sigma \approx 0.012 R_0^{0.935} \approx 4.31 \times 10^{-5} E_0^{1.636}$



Higher energy (range) Increased range straggling

#### **Range straggling**



# For water (in cm): $\sigma \approx 0.012 R_0^{0.935} \approx 4.31 \times 10^{-5} E_0^{1.636}$

#### @ 200 MeV, $\sigma = 2.5$ mm


81.4 (outer blue), 100.9 (middle orange), and 219.3 (inner yellow) MeV in a water phantom at 2 cm depth

E (MeV)	σ (mm)	FWHM (mm)
72.5	14.91	35.12
151.0	7.60	17.90
221.8	5.57	13.11

For the MD Anderson Proton Therapy Center, Houston, Texas (Hitachi Synchrotron)



81.4 (outer blue), 100.9 (middle orange), and 219.3 (inner yellow) MeV in a water phantom at 2 cm depth

E (MeV)	σ (mm)	FWHM (mm)
72.5	14.91	35.12
151.0	7.60	17.90
221.8	5.57	13.11

For the MD Anderson Proton Therapy Center, Houston, Texas (Hitachi Synchrotron)

#### Not really small pencils





Ideal

E = 150 MeV, simulated in water phantom



Ideal

E = 150 MeV, simulated in water phantom

40 -0.8 20 -- 0.6 (Em) x - 0.4 -20 - 0.2 -40 -50 100 150 200 z (mm)

Realistic

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

Material!

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

Material!

Large influence on stopping power

Lot of unknows...

$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

Material!

Large influence on stopping power

Lot of unknows...

What is the composition of human tissue?



$$S \equiv -\frac{\mathrm{d}E}{\mathrm{d}x} = C_1 \frac{Z}{A} \frac{1}{\beta^2} \left( \ln \frac{C_2 \beta^2}{I(1-\beta^2)} - \beta^2 \right)$$

For water, we assume I = 75 eV… or 78 eV (at least between 68 and 82 eV)

What is the composition of human tissue?

Large influence on stopping power

Lot of unknows...



Material!

#### **Proton therapy: what?**

Use of protons to deliver radiation dose Bragg peak: high dose in small volume

Pencil beams to deliver dose Size limited by physics

Knowlegde of body materials crucial Lot of unknowns

# III. Proton therapy: why?









Zelig Tochner, PTCOG 57







#### Lot of dose in healthy tissue = BAD

Zelig Tochner, PTCOG 57



Protons: no exit dose!

Combine multiple pencil beams, create a Spread-out Bragg Peak (SOBP)





#### Protons







# Protons

**IMRT** 

#### Less dose in healthy tissue

= GOOD





# Protons

**IMRT** 

Less dose in healthy tissue = GOOD

(unfortunately, bad *clinical* example, don't do this)

#### **Lower integral dose**



#### Better example: pediatrics

Lower integral dose, less toxicity and **less secondary cancer** 

#### **Lower integral dose**



T. DeLaney and R. Haas, Innovative radiotherapy of sarcoma: Proton beam radiation

Joris Hartman



Bussiere MR, Adams JA. **Treatment planning for conformal proton radiation therapy.** Technology in Cancer Research & Treatment 2:389-399. 2003



Bussiere MR, Adams JA. **Treatment planning for conformal proton radiation therapy.** Technology in Cancer Research & Treatment 2:389-399. 2003

Intensity Modulated Proton Therapy for Head and Neck Tumors: **Gilding the Lily or Holy Grail?** 



Quality of Life and Value Considerations in Head and Neck Proton Beam Therapy: **The Holy Grail at Last, or the Quest Continues**?

#### **Relative Biological Effectiveness (RBE)**



#### RBE



# ... but this value is far from constant

Francesco Tommasino and Marco Durante, Proton Radiobiology, Cancers 2015

Joris Hartman

#### RBE



Francesco Tommasino and Marco Durante, Proton Radiobiology, Cancers 2015

Joris Hartman

**Proton therapy: why?** 

Less integral dose but, not always best option

Less secondary cancers especially in, for example, pediatrics

Higher RBE but not completely understood



I. Planning

- I. Planning
- II. Production of protons



- I. Planning
- II. Production of protons
- III. Transport of protons



- I. Planning
- II. Production of protons
- III. Transport of protons
- IV. Delivery of protons to patient





Dedicated treatment planning software

Still mainly based on **analytical** beam models

Spots are determined, optimization based on goals:

- a) High, uniform dose to target
- b) Low dose to organs at risk, based on sensitivity of OAR

#### Number of fields (and angles) usually not optimized

Usually 2-5 fields per treatment plan

#### Based on CT and/or MR imaging

### Planning



### Planning



Joris Hartman

### **Production of protons**

#### (Synchro)cyclotron



#### or synchrotron


#### **Production of protons: cyclotron**



Energy usually around 250 MeV

Energy selection with degrader

#### Continuous beam

#### **Production of protons: cyclotron**



Energy usually around 250 MeV

Energy selection with degrader

Continuous beam

Activation

(no carbon yet)

Joris Hartman



Nikhef colloquium, 12-04-2019

Joris Hartman

### **Production of protons: synchrotron**

#### Adjustable energy



Low activation

(Carbon) ions

Limited intensity (average)

#### Large/expensive

Joris Hartman

#### **Production of protons**

Carbon Multiple particles Size (diameter) Intensity Fast E scanning Time structure Spot scanning

Continuous SS

#### Cyclotron

In development In development 3.5 - 5 m (SC < 2 m)Adjustable (SC: low) Degrader (activation) Cont (SC: pulsed) Yes

– Yes (SC: no)

Synchrotron Easy Easy 6 – 8 m (<sup>12</sup>C: 25m) Limited (per spill)

Next spill

Dead time

Yes

– Difficult

#### **Transport of protons**

Usually a single accelerator, shared by several gantries





Nikhef colloquium, 12-04-2019

Joris Hartman

#### **Transport of protons**

#### But systems with accelerator on gantry exist



Mevion S250

## **Delivery of protons**

Delivery, per field, of planned dose to target

Timing is dependent on a lot of parameters

- i. Target size
- ii. Number of spots per field
- iii. Dose to be delivered
- iv. Proton current
- V. ...

#### In the order of a few Gy per minute

## **Delivery of protons**



Dose distribution determined by **distal edge**.



## Dose distribution determined by individual Bragg Peaks.

## **Delivery of protons**





Dose distribution determined by **distal edge**.

Dose distribution determined by individual Bragg Peaks.

### **Delivery of protons: passive scattering**





Time intensive

Patient specific

Activation

## Non-optimal dose distribution

Becoming obsolete

## **Delivery of protons: scanning**



Less preparation

Not patient specific

Best dose distribution

All new machines

#### **Delivery of protons: scattering vs scanning**



**Passive scattering** 



3-field pencil beam scanning

Tony Lomax

Joris Hartman





Jay Flanz

Joris Hartman

i. Single Field Uniform Dose Optimization all fields deliver a uniform dose to the target

- i. Single Field Uniform Dose Optimization all fields deliver a uniform dose to the target
- ii. Multi Field Optimization every field may not be uniform, combined dose is



- i. Single Field Uniform Dose Optimization all fields deliver a uniform dose to the target
- ii. Multi Field Optimization every field may not be uniform, combined dose is



iii. Distal edge tracking Delivery to distal edge



loquium, 12-04-2019

Joris Hartman

#### **Proton therapy: how?**

#### Planning can be improved

still analytical and not all parameters are optimized

#### Cyclotron or synchrotron for protons no 'best' option

## Different techniques for delivery scanning is new standard

## **V. Challenges and developments**



### **Uncertainties**



#### Larger effect for protons

Knopf and Lomax

#### **Uncertainties**

- I. What tissue? Composition? Imaging!
- II. Motion

Compensation by breathold, repainting ('averaging'), gating, robust planning, tracking, so **imaging**!

III. Anatomical changes (tumor shrinkage, cavity filling)Compensation by replanning, imaging!

## **Current imaging**

#### **CT** has problems

- i. Low resolution
- ii. Low soft-tissue contrast
- iii. Ionizing radiation

## **Current imaging**

#### **CT** has problems

- i. Low resolution
- ii. Low soft-tissue contrast
- iii. Ionizing radiation

#### MRI had advantages

- i. Superior contrast
- ii. Good resolution
- iii. No ionizing radiation

## **Current imaging**

#### **CT** has problems

- i. Low resolution
- ii. Low soft-tissue contrast
- iii. Ionizing radiation

#### **MRI had advantages**

- i. Superior contrast
- ii. Good resolution
- iii. No ionizing radiation

#### and problems

- i. Relative values
- ii. Not easy to get stopping powers
- iii. Complicated technique



Based on MR-Linac, integrated MR - proton therapy system



Original philips design

## **MRI-guidance**

Based on MR-Linac, integrated MR - proton therapy system

#### **Problems:**

- A. Magnetic field effects on the Bragg Peak
  - i. Inside MR
  - ii. Fringe fields
- B. Steering magnets close to MR magnet?
- C. How do you get the protons inside MR?

Joris Hartman



Original philips design

## **MRI-guidance**

Based on MR-Linac, integrated MR - proton therapy system

#### **Problems:**

- A. Magnetic field effects on the Bragg Peak
  - i. Inside MR
  - ii. Fringe fields
- B. Steering magnets close to MR magnet?
- C. How do you get the protons inside MR?



Original philips design



#### **MRI-guidance: field effects**

#### Curvature



### **MRI-guidance: field effects**

Curvature

## So Bragg peak ends up at other location



### **MRI-guidance: field effects**

Curvature

So Bragg peak ends up at other location

Of course well known physics



# But.. not straightforward to determine position in tissue, espescially with analytical methods



# But.. not straightforward to determine position in tissue, espescially with analytical methods









Joris Hartman





Joris Hartman





Joris Hartman




Joris Hartman





Joris Hartman

#### No field





Difference



Joris Hartman

#### **Advantages**

- i. Monte Carlo gives highest precision
- ii. You get magnetic field 'for free'

#### **Advantages**

- i. Monte Carlo gives highest precision
- ii. You get magnetic field 'for free'

Disadvantage: slow...

#### **Advantages**

- i. Monte Carlo gives highest precision
- ii. You get magnetic field 'for free'

Disadvantage: slow...

#### Solutions

- i. GPU MC
- ii. Simplification

Joris Hartman

#### **Magnetic fields: beam entrance**





#### **Magnetic fields: complicated**



Joris Hartman

### **Magnetic fields: complicated**



## **Heavy particles**



A. Kohler

## **Heavy particles**



A. Kohler



Joris Hartman





#### Carbon gantry HIT (Heidelberg)

- Only in the world
- 25 x 13 meters
- 670 tons
- 360° rotation
- 425 MeV/u



Carbon gantry HIT (Heidelberg)

- Only in the world
- 25 x 13 meters
- 670 tons
- 360° rotation
- 425 MeV/u



Carbon gantry HIT (Heidelberg)

- Only in the world
- 25 x 13 meters
- 670 tons
- 360° rotation
- 425 MeV/u

**Other developments** 

Proton imaging

In-vivo range verification

Further focus on particle therapy (with immunotherapy)

More compact accelerators

**Other developments** 

Proton imaging

In-vivo range verification

Further focus on particle therapy (with immunotherapy)

More compact accelerators

#### And more... a lot of research is going on!

Joris Hartman

# **Questions?**